Description

FIASP FLEXTOUCH 100U/3ML

Indications

FIASP FLEXTOUCH 100U/3ML is an insulin formulation indicated for the treatment of diabetes mellitus in adults and children aged 1 year and older. It is specifically designed for the management of both type 1 and type 2 diabetes, providing rapid reduction of blood glucose levels. This product is particularly beneficial for individuals requiring mealtime insulin to control postprandial hyperglycemia.

Mechanism of Action

FIASP is a fast-acting insulin aspart formulation that mimics the physiological insulin response to meals. The active ingredient, insulin aspart, is a modified form of human insulin that has a rapid onset of action. Upon administration, FIASP quickly lowers blood glucose levels by facilitating the uptake of glucose into muscle and fat tissues while inhibiting hepatic glucose production. The formulation is designed to be injected just before or immediately after meals, providing flexibility in timing for patients.

Pharmacological Properties

FIASP FLEXTOUCH 100U/3ML contains insulin aspart, which is characterized by its rapid absorption and action profile. The pharmacokinetic properties of FIASP include a time to peak concentration of approximately 1-3 hours post-injection, with a duration of action lasting up to 5 hours. This rapid action is attributed to the formulation’s unique excipients, which enhance the solubility and absorption of insulin aspart. The product is available in a pre-filled pen device, allowing for convenient and accurate dosing.

Contraindications

FIASP FLEXTOUCH should not be used in patients with hypersensitivity to insulin aspart or any of the excipients in the formulation. Additionally, it is contraindicated in individuals experiencing episodes of hypoglycemia, as the administration of insulin in such cases can exacerbate the condition. Caution is advised in patients with renal or hepatic impairment, as these conditions may affect insulin metabolism and clearance.

Side Effects

The most common side effects associated with FIASP FLEXTOUCH include hypoglycemia, which can manifest as symptoms such as sweating, tremors, palpitations, and confusion. Other potential side effects may include injection site reactions (e.g., redness, swelling, or itching), weight gain, and allergic reactions. Rare but severe adverse effects can include anaphylaxis and severe hypoglycemia, which may require immediate medical attention. Patients should be educated on recognizing the signs of hypoglycemia and the appropriate steps to take in case of an episode.

Dosage and Administration

The dosage of FIASP FLEXTOUCH is individualized based on the patient’s needs, blood glucose monitoring results, and dietary habits. It is typically administered subcutaneously into the abdominal area, thigh, or upper arm. The recommended starting dose for adults with type 1 diabetes is usually based on their total daily insulin requirement, while for type 2 diabetes, it may be initiated at a lower dose and adjusted based on glycemic control. Patients should be instructed to inject FIASP immediately before or within 20 minutes after starting a meal to optimize glucose control.

Interactions

FIASP FLEXTOUCH may interact with various medications that can either potentiate or diminish the hypoglycemic effect of insulin. Drugs such as corticosteroids, thiazide diuretics, and certain antipsychotics can increase blood glucose levels, potentially necessitating adjustments in insulin dosing. Conversely, medications such as sulfonylureas, beta-blockers, and alcohol can enhance the risk of hypoglycemia. It is essential for patients to inform their healthcare providers of all medications they are taking to ensure safe and effective management of their diabetes.

Precautions

Patients using FIASP FLEXTOUCH should be monitored closely for signs of hypoglycemia, particularly during periods of increased physical activity, changes in diet, or illness. It is crucial for patients to maintain regular blood glucose monitoring to adjust their insulin doses as needed. Additionally, patients with a history of hypoglycemic episodes should be educated on the importance of carrying fast-acting carbohydrates at all times. Special care should be taken in populations such as the elderly, pregnant women, and those with renal or hepatic impairment, as they may be at increased risk for adverse effects.

Clinical Studies

Clinical studies have demonstrated the efficacy and safety of FIASP FLEXTOUCH in managing blood glucose levels in patients with diabetes. In a multi-center, randomized clinical trial, FIASP was shown to provide superior postprandial glucose control compared to regular insulin aspart, with a similar safety profile. Another study highlighted the flexibility of FIASP administration, showing that patients could achieve optimal glycemic control with less risk of hypoglycemia when using FIASP compared to other rapid-acting insulins. These studies support the use of FIASP FLEXTOUCH as an effective option for individuals requiring mealtime insulin therapy.

Conclusion

FIASP FLEXTOUCH 100U/3ML is a rapid-acting insulin formulation that offers an effective solution for the management of diabetes mellitus. With its unique pharmacological properties and convenient delivery system, it allows for flexible dosing around mealtimes, making it an essential tool for patients aiming to achieve optimal glycemic control. However, careful monitoring and patient education are vital to minimize the risk of adverse effects and ensure safe usage.